Literature DB >> 17828622

Treatment-competing events in dynamic regimes.

Brent A Johnson1.   

Abstract

A dynamic treatment regime is a sequence of decision rules for assigning treatment based on a patient's current need for treatment. Dynamic regimes are viewed, by many, as a natural way of treating patients with chronic diseases; that is, treating patients with adaptive, complex, longitudinal treatment regimens. In developing dynamic treatment strategies, treatment-competing events may play an important role in the overall treatment strategy, and their effects on subsequent treatment decisions and eventual outcome should be considered. Treatment-competing events may be defined generally as patient-specific, random events which interrupt the ongoing treatment decision process in a dynamic regime. Treatment-competing events censor later treatment decisions that would otherwise be made on a particular dynamic treatment regime had the competing events not occurred. For example, in therapeutic studies of HIV, physicians may assign treatment based on a patient's current level HIV1-RNA; this defines a treatment assignment rule. However, the presence of opportunistic infections or severe adverse events may preclude a strict adherence of the treatment assignment rule. In other contexts, the "censoring"-by-death phenomenon may be viewed as an example of a treatment-competing event for a particular dynamic treatment regime. Treatment-competing events can be built into the dynamic treatment regime framework and counting processes are a natural mechanism to facilitate this development. In this paper, we develop treatment-competing events in a dynamic infusion policy, a random dynamic treatment regime where multiple infusion treatments are initiated simultaneously and given continuously over time subject to the presence/absence of a treatment-competing event. We illustrate how our methodology may be used to suggest an estimator for a particular causal estimand of recent interest. Finally, we exemplify our methods in a recent study of patients undergoing coronary stent implantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17828622     DOI: 10.1007/s10985-007-9051-3

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  4 in total

1.  Estimating mean response as a function of treatment duration in an observational study, where duration may be informatively censored.

Authors:  Brent A Johnson; Anastasios A Tsiatis
Journal:  Biometrics       Date:  2004-06       Impact factor: 2.571

2.  Tourette syndrome: diagnosis, strategies, therapies, pathogenesis, and future research directions.

Authors:  Lori L Olson; Harvey S Singer; Wayne K Goodman; Bernard L Maria
Journal:  J Child Neurol       Date:  2006-08       Impact factor: 1.987

3.  Marginal Mean Models for Dynamic Regimes.

Authors:  S A Murphy; M J van der Laan; J M Robins
Journal:  J Am Stat Assoc       Date:  2001-12-01       Impact factor: 5.033

4.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

  4 in total
  2 in total

1.  Relationship between anticholinergic drug use and one-year outcome among elderly people hospitalised in medical wards via emergency department: the SAFES cohort study.

Authors:  D Narbey; D Jolly; R Mahmoudi; T Trenque; F Blanchard; J-L Novella; M Dramé
Journal:  J Nutr Health Aging       Date:  2013-09       Impact factor: 4.075

2.  Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times.

Authors:  Brent A Johnson; Heather Ribaudo; Roy M Gulick; Joseph J Eron
Journal:  Biometrics       Date:  2013-07-17       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.